School of Medicine
Showing 51-100 of 166 Results
-
Mary Leonard
Arline and Pete Harman Professor and Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy multidisciplinary research program is focused on (1) the detrimental effects of glucocorticoids, sarcopenia and inflammation on bone development in pediatric diseases, (2) the long-term effects of childhood cancer on bone and muscle quality, (3) the assessment of renal osteodystrophy using novel micro-imaging techniques, (4) the effects of vitamin D deficiency on physical function and cardiovascular disease, and (5) the evaluation of biomechanical interventions as anabolic bone therapies.
-
John Leppert
Professor of Urology and, by courtesy, of Nephrology
Current Research and Scholarly InterestsOur research aims to improve the global quality of care for patients with Urologic Cancer with a particular focus on kidney cancer. We are investigating novel proteomic platforms and assays to diagnose kidney cancer and predict response to therapy. We are evaluating the comparative effectiveness of various kidney cancer surgeries and their impact on chronic kidney disease and its downstream effects. We are applying epidemiology, bioinformatics, and health services methods to urologic conditions.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Eleanor Levin
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardiovascular Value Based Care, Cardio-Obstetrics, Dyslipidemia Treatment
-
Deborah J Levine, MD, FCCP, FAST
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
BioDr. Deborah Jo Levine is a board-certified pulmonologist and lung transplantation and pulmonary hypertension specialist. She is a clinical professor of medicine in the Department of Pulmonary, Allergy, and Critical Care Medicine. Dr. Levine also serves as director of lung transplant outreach for Stanford Health Care.
Dr. Levine is internationally recognized for her work in lung transplantation and pulmonary hypertension (PH). She has been instrumental in developing international guidelines for defining, diagnosing, and managing antibody-mediated rejection (AMR) after lung transplantation. She has served as chair of pulmonary AMR guidelines for the International Society of Heart and Lung Transplantation.
Dr. Levine’s research interests include lung allograft monitoring and risk assessment. Her research has also included monitoring lung allograft health using donor-derived cell-free DNA (dd-cfDNA)—a technique pioneered at Stanford Medicine. She has received National Institutes of Health (NIH) funding as a clinical investigator. Dr. Levine is a co-chair of the ALAMO (AlloSure Lung Assessment and Metagenomics Outcomes) Study national registry. She has been involved in many clinical trials in lung transplantation and pulmonary hypertension.
As a respected educator and researcher, Dr. Levine has led and contributed to dozens of abstracts, presentations, and peer-reviewed articles. She has also written several books and book chapters on pulmonary hypertension, interstitial lung disease, pulmonary vascular disorders, and lung transplantation.
Dr. Levine is editor-in-chief for Advances in Pulmonary Hypertension, the quarterly journal of the Pulmonary Hypertension Association. She is an editorial board member of The Journal of Heart and Lung Transplantation and an ad hoc reviewer for several other industry journals. Dr. Levine also serves as a grant reviewer and section study reviewer for the American College of Chest Physicians and the American Society of Transplantation.
Dr . Levine is a fellow of the American College of Chest Physicians and the American Society of Transplantation. She is also the chair of the Diffuse Lung Disease and Lung Transplant Network and the incoming vice chair of the Council of Networks for the American College of Chest Physicians (CHEST). -
Joseph Levitt, MD, MS
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsMy research focuses on the physiolgogic and biomarker characteristics of early acute lung injury (ALI) prior to need for mechanical ventilation. While, to date no pharmacologic treatment has improved survival in ALI, following the paradigm of early goal directed therapy for severe sepsis, clinical benefit may derive from identifying patients and initiating treatment prior to the need for positive pressure ventilation (and therefore prior to meeting current study entry criteria).
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly InterestsLow molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
On Partial Leave from 05/16/2024 To 05/15/2025Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Vivian Levy
Clinical Associate Professor (Affiliated), Medicine - Med/Infectious Diseases
Staff, Medicine - Med/Infectious DiseasesBioVivian Levy is Chief of Infectious Diseases at San Mateo Medical Center (SMMC), San Mateo County’s safety net hospital and clinic system in northern California since 2015 and the County’s STD Control Officer since 2006. San Mateo County has 760,000 persons and connects the urban centers of San Francisco and San Jose, California.
Dr. Levy leads Stanford’s Internal Medicine outpatient Infectious Diseases rotation for Internal Medicine residents. She has served 2 terms as president of the California STD/HIV Controllers Association. From 2004-2008, she was the medical officer for the Chemoprophylaxis for HIV prevention in men study in Lima, Peru.
In 2020, she was the San Mateo Medical Center site investigator for the Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 Infection. She began SMMC patient recruitment for Stanford outpatient COVID studies July 2020 with the goal of increasing historically underrepresented populations participation and access in COVID outpatient treatment trials.
She has an undergraduate degree from Brown University (1989,) an MD from Rush University Medical College in Chicago (1994,) completed internship in Internal Medicine at Cook County Hospital in Chicago (1995) Internal Medicine residency at Northwestern University (1997) and an Infectious Diseases and Geographic Medicine fellowship at Stanford University (2000-2004.) -
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Nina Li
Community Program Manager, Stanford CARE, Medicine - Med/Family and Community Medicine
Current Role at StanfordCommunity Program Manager, Stanford CARE
-
Ron Li
Clinical Associate Professor, Medicine
BioRon Li is a Clinical Associate Professor of Medicine in the Division of Hospital Medicine and Center for Biomedical Informatics Research at Stanford University School of Medicine. As the Medical Informatics Director for Digital Health at Stanford Health Care, he provides medical and informatics direction for the health system's enterprise digital health portfolio, including expanding digital referral networks and virtual care modalities. He is the co-founder and Director for the Stanford Emerging Applications Lab (SEAL), which helps clinicians and staff build ideas into novel digital products that are prototyped and tested for care delivery at Stanford Health Care.
Ron's academic interests focus on the "delivery science" of new technological capabilities such as digital and artificial intelligence in healthcare and how to design, implement, and evaluate new tech enabled models of care delivery. Ron's work spans across multiple disciplines, including clinical medicine, data science, digital health, information technology, design thinking, process improvement, and implementation science. He has consulted for various companies in the digital health and artificial intelligence space. He is an attending physician on the inpatient medicine teaching service at Stanford Hospital and is the Associate Program Director for the Stanford Clinical Informatics Fellowship. -
Sally S. Li
Executive Director, Medicine - Med/Family and Community Medicine
Current Role at StanfordExecutive Director, Center for Asian Health Research and Education (CARE)
-
David Liang, MD, PhD
Professor of Medicine (Cardiovascular) at the Stanford University Medical Center, Emeritus
BioStanford researchers are creating a micro-device that physicians could guide through the body to help diagnose and treat clogged arteries and other diseases. Tethered to the outside world by a thin wire, a tiny machine creeps through blood vessels, searching out deadly plaques and obliterating them with a zap of a laser. While a laser will come later, for now David Liang, MD, PhD, is focusing on a tiny eye that could give physicians an unprecedented view into blood vessels.
-
Charles Liao
Clinical Assistant Professor, Medicine
Current Research and Scholarly InterestsEducational Curriculum: Working with Professional Interpreters
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
Michaela Liedtke
Associate Professor of Medicine (Hematology)
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis -
Joanna E. Liliental, PhD
Director, TRAM, M-TRAM, TASC, Med/TRAM
Current Role at StanfordExecutive Director, Master's in TRAM (M-TRAM)
https://med.stanford.edu/tram/masters-program.html
Director, Translational Applications Service Center (TASC)
http://tasc.stanford.edu
Associate Director, Translational Research and Applied Medicine (TRAM) Program
http://tram.stanford.edu
Senior Research Scientist, Stanford School of Medicine
Instructor of University Courses: MED221,MED121, MED212A
Member, Stanford Cancer Institute -
Michael Lim, M.D.
Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
